The Leukemia Division, established in 2000, has had a seminal role in the development of novel therapies for several types of leukemia, particularly chronic myeloid leukemia, acute myeloid leukemia, chronic lymphocytic leukemia and myelodysplasia.
The leukemia team together with outstanding hematopathologists, infectious disease specialists, a research-dedicated team, as well as one of the largest bone marrow transplant programs in the world, is able to provide options for all patients with leukemia including the most challenging cases where patients have failed prior therapy.
Dr Stuart Goldberg has been a pioneer, particularly in CML and MDS and the founder of the Leukemia Division. Dr Stefan Faderl, after 16 years at MD Anderson, Houston, TX, as a Professor of Medicine in the largest Leukemia Program in the world, joined us in 2014 to lead JTCC Leukemia Program. He is an internationally known investigator in the field and has authored the most recent comprehensive book on leukemia.